Moderna (MRNA) EBITDA (2017 - 2026)

Moderna (MRNA) has 10 years of EBITDA data on file, last reported at -$1.4 billion in Q1 2026.

• On a quarterly basis, EBITDA fell 32.19% year-over-year to -$1.4 billion in Q1 2026; TTM through Mar 2026 was -$3.4 billion, a 8.5% increase from a year earlier, with the FY2025 full-year figure at -$3.1 billion, up 22.08% from the prior year.
• EBITDA for Q1 2026 stood at -$1.4 billion, down from -$857.0 million in the prior quarter.
• Over the last five years, EBITDA for MRNA reached as high as $4.2 billion in Q1 2022 and fell as low as -$2.0 billion in Q3 2023.
• Historically, EBITDA has averaged -$189.8 million across 5 years, with a median of -$857.0 million in 2025.
• Across the five-year window, EBITDA surged 233.89% in 2022 and plunged 20866.67% in 2024, its largest moves.
• Year by year, EBITDA stood at $1.6 billion in 2022, then sank by 99.62% to $6.0 million in 2023, then plunged by 20866.67% to -$1.2 billion in 2024, then jumped by 31.22% to -$857.0 million in 2025, then tumbled by 61.96% to -$1.4 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were -$1.4 billion in Q1 2026, -$857.0 million in Q4 2025, and -$260.0 million in Q3 2025.